|Bid||0.00 x 2075500|
|Ask||0.00 x 1250000|
|Day's range||12.50 - 12.50|
|52-week range||6.05 - 29.40|
|Beta (5Y monthly)||-1.82|
|PE ratio (TTM)||11.14|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Co-Diagnostics (NASDAQ: CODX), considered a coronavirus stock because of its COVID-19 testing products, was up by nearly 9% in midafternoon trading on Wednesday. The test, which has Emergency Use Authorization from the Food and Drug Administration, harnesses Co-Diagnostics' patented testing technology. In Walgreens' announcement, the company quoted Clinical Reference Laboratory CEO Robert Thompson as saying that the test "demonstrated highly accurate results with 100% sensitivity and specificity in its FDA EUA filing."
Tuesday was a busy day in the upper managerial ranks of Co-Diagnostics (NASDAQ: CODX). The molecular diagnostics specialist appointed both a new CFO and a new chief science officer (CSO). The former is Brian Brown, who replaces current office holder Reed Benson.
Telephone and Data Systems (NYSE: TDS), Tri Pointe Homes (NYSE: TPH), and Co-Diagnostics (NASDAQ: CODX) all have modest share prices yet stand on solid ground. The company did an excellent job of keeping costs down, so net income was $254 million, up 92% compared to the same period in 2019.